Charles Chapman

发表

A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model

D. Lorrain, P. Prasit, T. J. Seiders, 2010, British journal of pharmacology.

Pharmacokinetic and Pharmacodynamic Characterization of an Oral Lysophosphatidic Acid Type 1 Receptor-Selective Antagonist

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of Pharmacology and Experimental Therapeutics.

Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Bioorganic & medicinal chemistry letters.

5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of medicinal chemistry.

5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).

Jilly F. Evans, D. Lorrain, P. Prasit, 2009, Journal of medicinal chemistry.

Pharmacokinetic and Pharmacodynamic Characterization of an Oral Lysophosphatidic Acid Type 1 Receptor-Selective Antagonist

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of Pharmacology and Experimental Therapeutics.

Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation.

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, European journal of pharmacology.

Pharmacological Characterization of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103), a Novel Selective 5-Lipoxygenase-Activating Protein Inhibitor That Reduces Acute and Chronic Inflammation

Jilly F. Evans, D. Lorrain, C. King, 2009, Journal of Pharmacology and Experimental Therapeutics.

5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)-A potent FLAP inhibitor suitable for topical administration.

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, Bioorganic & medicinal chemistry letters.

5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, Bioorganic & medicinal chemistry letters.